Objective: To identify factors associated with receiving electroconvulsive therapy (ECT) for serious psychiatric conditions.

Methods: Retrospective observational study using hospital administrative data linked with death registrations and outpatient mental health data in New South Wales (NSW), Australia. The cohort included patients admitted with a primary psychiatric diagnosis between 2013 and 2022. The outcome measure was receipt of ECT.

Results: Of 94,950 patients, 3465 (3.6%) received ECT. The likelihood of receiving ECT was higher in older (hazard ratio [HR] = 1.03), female (HR = 1.24) patients. Compared to depression, patients with schizophrenia/schizoaffective disorder (HR = 0.79), schizophrenia-related disorders (HR = 0.37), mania (HR = 0.64) and other mood disorders (HR = 0.45) had lower odds of receiving ECT. Patients with depression and one other serious psychiatric condition had higher odds of receiving ECT than depression alone. Bipolar disorder likelihood of ECT did not differ from depression. A higher number of mental health outpatient visits in the prior year and an involuntary index admission with depression were also associated with receiving ECT. Likelihood of receiving ECT increased with year of admission (HR = 1.32), private patient status (HR = 2.06), higher socioeconomic status (HR = 1.09) and being married (HR = 1.25).

Conclusions: ECT use for depression and bipolar disorder in NSW aligns with clinical national guidelines. Patients with schizophrenia/schizoaffective, schizophrenia-related disorders, mania and other mood disorders had lower likelihood of ECT than depression, despite ECT being recommended by clinical guidelines for these diagnoses. Variations in ECT were strongly associated with healthcare access, with private patients twice as likely to receive ECT than their public counterparts, suggesting a need to explore ECT accessibility.

Download full-text PDF

Source
http://dx.doi.org/10.1177/00048674241266067DOI Listing

Publication Analysis

Top Keywords

receiving ect
20
ect
14
serious psychiatric
12
ect depression
12
factors associated
8
electroconvulsive therapy
8
associated receiving
8
mental health
8
ect likelihood
8
likelihood receiving
8

Similar Publications

Electroconvulsive Therapy-Induced Mania in Bipolar Disorder: A Case Report.

Cureus

December 2024

Psychiatry, Psychiatrisch Ziekenhuis Asster, Sint-Truiden, BEL.

Electroconvulsive therapy (ECT) is widely recognized as a safe and effective intervention for treating severe affective episodes in patients with bipolar disorder. However, it can sometimes precipitate unexpected manic phases in patients treated for a depressive episode, a phenomenon known as ECT-induced mania. While this occurrence is recognized, it remains poorly understood and minimally addressed in the literature.

View Article and Find Full Text PDF

Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.

Am J Psychiatry

January 2025

Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore (Aaronson, Miller, LaPratt, Swartz, Shoultz, Lauterbach); Department of Psychiatry, University of Maryland, Baltimore (Aaronson, van der Vaart, Lauterbach); VA Palo Alto Health Care System and Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine, Palo Alto, CA (Suppes); Departments of Psychiatry and Radiology, Columbia University, New York (Sackeim).

Article Synopsis
  • The study focused on evaluating the safety and effectiveness of psilocybin for patients with severe treatment-resistant depression (TRD), who had not benefited from at least five previous treatments.
  • Conducted over 12 weeks at Sheppard Pratt Hospital, patients received a single 25 mg dose of synthetic psilocybin and underwent therapy sessions before and after dosing, assessing their depression levels mainly with the Montgomery-Åsberg Depression Rating Scale (MADRS).
  • Results showed significant reductions in depressive symptoms at both 3 weeks and 12 weeks post-treatment, indicating psilocybin’s potential as a viable option for individuals with severe TRD, although those with comorbid PTSD experienced less improvement.
View Article and Find Full Text PDF

This systematic review and network meta-analysis (NMA) sought to compare different antidepressant treatments for treatment-resistant depression (TRD) in order to facilitate evidence-based choices. A literature search of PubMed, Cochrane Library, and Embase from inception until April 13th, 2023 identified randomized, controlled trials (RCTs) of adults with depression who had not responded to at least two antidepressant trials; all RCTs had ≥10 participants per study arm, and participants with bipolar or psychotic depression were excluded. The Cochrane Risk of Bias Tool-2 was used to assess study quality.

View Article and Find Full Text PDF

Pilot Study of Cerebral Hemodynamics in Depressive Patient Under Electroconvulsive Therapy.

Neuropsychiatr Dis Treat

December 2024

Research Center of Educational Neuroscience, School of Educational Science, Huazhong University of Science and Technology, Wuhan City, Hubei Province, People's Republic of China.

Article Synopsis
  • Major depressive disorder (MDD) is a complex condition that can be hard to treat, and Electroconvulsive therapy (ECT) shows promise but its workings are not fully understood.
  • This study used functional Near-Infrared Spectroscopy (fNIRS) to compare the brain activity of a male MDD patient to that of 26 healthy controls before and after ECT, focusing on how ECT affects cerebral blood flow and brain networks.
  • Results indicated that the MDD patient had lower brain activity and connectivity at the start, but after ECT, these measures improved significantly, suggesting that ECT can effectively alter brain function in depressed patients and that fNIRS is a valuable tool for studying these changes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!